Published in Hepatology on February 01, 2013
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol (2015) 1.67
The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76
Reply: To PMID 21294144. Hepatology (2013) 0.75
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Examination of claudin-1 expression in patients undergoing liver transplantation owing to hepatitis C virus cirrhosis. Transplant Proc (2011) 1.08
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol (2005) 1.49
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Iron overload, inflammation and fibrosis in genetic haemochromatosis. J Hepatol (2003) 1.45
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med (2004) 1.43
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (2012) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol (2004) 1.23
Hepatitis C virus entry: beyond receptors. Rev Med Virol (2012) 1.23
Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol (2002) 1.19
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology (2009) 1.17
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol (2008) 1.12
Development of novel therapies for hepatitis C. Antiviral Res (2010) 1.09
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol (2006) 1.04
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol (2009) 1.04
Current views on rejection pathology in liver transplantation. Transpl Int (2010) 1.03
Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol (2012) 1.02
Hepatitis C virus entry and neutralization. Clin Liver Dis (2008) 1.02
Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol (2002) 1.00
A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol (2011) 1.00
Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology (2013) 0.99
An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology (2013) 0.96
Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis (2011) 0.93
Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol (2014) 0.90
Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J Hepatol (2013) 0.90
Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int (2008) 0.90
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol (2013) 0.89
Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology (2014) 0.88
Mechanisms of viral entry: sneaking in the front door. Protoplasma (2010) 0.88
Over the fence or through the gate: how viruses infect polarized cells. Immunotherapy (2012) 0.88
Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. Mol Pharm (2014) 0.86
Hepatitis C virus entry and the tetraspanin CD81. Biochem Soc Trans (2011) 0.86
Structural characterization of recombinant human CD81 produced in Pichia pastoris. Protein Expr Purif (2007) 0.85
In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface. Cell Microbiol (2012) 0.85
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open (2013) 0.83
Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Hepatology (2011) 0.83
Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl (2006) 0.83
Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl (2008) 0.82
The complexities of hepatitis C virus entry. J Hepatol (2009) 0.80
In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. J Hepatol (2006) 0.79
Production, purification and characterization of recombinant, full-length human claudin-1. PLoS One (2013) 0.78
Cytokeratin expression as an aid to diagnosis in medical liver biopsies. Histopathology (2010) 0.78